300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Africa
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Pakistan
Sudan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Malta
Luxembourg
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
TCD Capital, VC Fund

TCD Capital

VC Fund

Uccle, Belgium

TCD Capital is a VC fund in Uccle focused on Biotechnology and Health Care. TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.

Total investments:
18
Last investment:
Lead investor:
33%
Fund size:
$49M
Last fund:

Last updated:

Industries TCD Capital invests in

BiotechnologyHealth CareMedical DeviceClinical TrialsInformation Technology

Stages TCD Capital invests in

Series ASeries BVenture - Series UnknownSeedSeries C

Countries TCD Capital invests in

BelgiumFrance

Round sizes

Series A $2.1M–$7.7MSeries B $13M–$19MVenture - Series Unknown $5.5M–$6.5M

Contacts

NameEmailPhoneSocials
See all 7 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2.1M–$7.7M
Series B
$13M–$19M
Venture - Series Unknown
$5.5M–$6.5M

Investment Focus

Industry

  • Biotechnology 4 (22%)
  • Health Care 3 (17%)
  • Medical Device 2 (11%)
  • Clinical Trials 2 (11%)
  • Information Technology 2 (11%)
See all 31 industries →

Stage

  • Series A 9 (50%)
  • Series B 2 (11%)
  • Venture - Series Unknown 2 (11%)
  • Seed 1 (6%)
  • Series C 1 (6%)
See all 6 stages →

Country

  • Belgium 10 (56%)
  • France 4 (22%)

Team

NameTitleInvestmentsLinksEmail
Jean-Louis Dubrule Executive partner and Board Member
Executive partner and Board Member Total investments: 0
Find email
Jean-Marc Legrand Founder & Managing Director
Founder & Managing Director Total investments: 0
Find email
Xavier de Villepin
Xavier de Villepin Business & Investment Manager
Business & Investment Manager Total investments: 0
Find email
Edouard de Becker Remy
Edouard de Becker Remy Investment Analyst
Investment Analyst Total investments: 0
Find email
Frederic Convent Senior Investment Manager
Senior Investment Manager Total investments: 0
Find email
See all 7 team members →

Investments

CompanyDescriptionRoundLinks
Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. $6.5M / Venture - Series Unknown / Oct 29, 2024
CLOUDS OF CARE aids HealthTech firms from algorithm validation to medical device software, focusing on regulatory compliance. $5.5M / Venture - Series Unknown / Sep 04, 2024
Inpulse is an automated supply management platform for restaurateurs. $7.7M / Series A / Apr 19, 2023
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. $43.3M / Series D / Oct 17, 2022
FLYX.cloud enables retail chains to maximise value from each customer in multiple industries (such as Food, Grocery and Fuel) and in an omni-channel sales model. $2.1M / Series A / Jun 01, 2022
Smartflats constructs and distributes a range of flats for its clients.The company provides its users with an online platform to make bookings for their stay. It enables them to make food orders and obtain transfer services. Furthermore, it provides wireless internet, TVs, coffee makers, irons, and hairdryers.Smartflats was founded in 2012 byTarik Hennen and Alexandre Szmaj. $4.9M / Series A / Oct 01, 2021
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketingsuccess.Start your search now on www.sortlist.com $13M / Series B / Sep 15, 2021
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. $24.5M / Series C / Dec 17, 2020
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. Series C / Aug 31, 2020
Co-Living, Smart Living Seed / Apr 30, 2019
See all 18 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Africa
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Pakistan
Sudan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Malta
Luxembourg
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Paraguay
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does TCD Capital invest in?

TCD Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does TCD Capital invest in?

TCD Capital typically joins rounds of $2.1M–$7.7M at Series A, $13M–$19M at Series B and $5.5M–$6.5M at Venture - Series Unknown. These are whole funding-round sizes, not TCD Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds TCD Capital took part in.

How do I contact TCD Capital?

Public channels for TCD Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at TCD Capital?

The team at TCD Capital includes Jean-Louis Dubrule (Executive partner and Board Member), Jean-Marc Legrand (Founder & Managing Director) and Xavier de Villepin (Business & Investment Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
TCD Capital TCD Capital Find emails